Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II — data from the Hunter Outcome Survey
- 1 October 2010
- journal article
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 101 (2-3) , 123-129
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidosesMolecular Genetics and Metabolism, 2009
- Home treatment with Elaprase® and Naglazyme® is safe in patients with mucopolysaccharidoses types II and VI, respectivelyJournal of Inherited Metabolic Disease, 2008
- Initial report from the Hunter Outcome SurveyGenetics in Medicine, 2008
- A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)Molecular Genetics and Metabolism, 2007
- A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)Genetics in Medicine, 2006
- Intravenous enzyme replacement therapy: better in home or hospital?British Journal of Nursing, 2006
- Cumulative incidence rates of the mucopolysaccharidoses in GermanyJournal of Inherited Metabolic Disease, 2005
- Home treatment for Fabry disease: practice guidelines based on 3 years experience in The NetherlandsNephrology Dialysis Transplantation, 2005
- The frequency of lysosomal storage diseases in The NetherlandsHuman Genetics, 1999
- The Defect in the Hunter Syndrome: Deficiency of Sulfoiduronate SulfataseProceedings of the National Academy of Sciences, 1973